Cargando…
A Dual TLR7/TLR9 Inhibitor HJ901 Inhibits ABC-DLBCL Expressing the MyD88 L265P Mutation
Diffuse large B cell lymphoma (DLBCL) is associated with aggressive clinical cases and poor prognosis despite recent advances in disease treatment. In activated B-cell-like (ABC)-DLBCL, the most severe damaged signaling pathways converge to aberrantly activate the Toll-like receptor (TLR) 7/9/MyD88...
Autores principales: | An, Beiying, Zhu, Shan, Li, Tete, Wu, Jing, Zang, Guoxia, Lv, Xinping, Qiao, Yuan, Huang, Jing, Shao, Yan, Cui, Jiuwei, Liu, Yong-Jun, Chen, Jingtao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7188833/ https://www.ncbi.nlm.nih.gov/pubmed/32391356 http://dx.doi.org/10.3389/fcell.2020.00262 |
Ejemplares similares
-
Inflammatory Role of TLR-MyD88 Signaling in Multiple Sclerosis
por: Zheng, Chao, et al.
Publicado: (2020) -
MyD88 and TLR4 Expression in Epithelial Ovarian Cancer
por: Block, Matthew S., et al.
Publicado: (2018) -
Soyasaponins reduce inflammation by downregulating MyD88 expression and suppressing the recruitments of TLR4 and MyD88 into lipid rafts
por: Chen, Junbin, et al.
Publicado: (2020) -
From monogenic lupus to TLR7/MyD88-targeted therapy
por: Wang, Min, et al.
Publicado: (2022) -
pDC Activation by TLR7/8 Ligand CL097 Compared to TLR7 Ligand IMQ or TLR9 Ligand CpG
por: Wu, Jing, et al.
Publicado: (2019)